Savant Capital LLC Takes $52,000 Position in Neumora Therapeutics, Inc. $NMRA

Savant Capital LLC purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 2nd quarter, HoldingsChannel reports. The firm purchased 70,432 shares of the company’s stock, valued at approximately $52,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NMRA. Jump Financial LLC acquired a new stake in Neumora Therapeutics in the first quarter valued at approximately $25,000. CWM LLC lifted its stake in shares of Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company’s stock valued at $25,000 after purchasing an additional 24,864 shares during the last quarter. Aigen Investment Management LP acquired a new position in Neumora Therapeutics during the first quarter worth $36,000. Virtu Financial LLC bought a new position in Neumora Therapeutics during the first quarter valued at about $40,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Neumora Therapeutics in the second quarter worth about $42,000. Institutional investors own 47.65% of the company’s stock.

Insider Buying and Selling

In other news, Director Kristina Burow acquired 1,915,700 shares of Neumora Therapeutics stock in a transaction on Monday, October 27th. The stock was bought at an average price of $2.61 per share, for a total transaction of $4,999,977.00. Following the transaction, the director owned 6,046,907 shares of the company’s stock, valued at $15,782,427.27. The trade was a 46.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Daljit Singh Aurora sold 114,703 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total value of $307,404.04. The disclosure for this sale is available in the SEC filing. 26.80% of the stock is owned by company insiders.

Neumora Therapeutics Trading Down 1.3%

Shares of NMRA stock opened at $2.33 on Friday. The firm has a market capitalization of $389.32 million, a P/E ratio of -1.59 and a beta of 2.98. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $11.57. The firm’s fifty day simple moving average is $2.16 and its 200 day simple moving average is $1.56. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). As a group, sell-side analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NMRA. JPMorgan Chase & Co. lowered Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, September 16th. Needham & Company LLC increased their price target on Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Stifel Nicolaus upped their price objective on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Finally, Guggenheim upgraded shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.57.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.